Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Beringer

Neurological Surgery Kailua, HI Medical Doctor

NPI 1073655221 CMS profile 3032

40 Aulike St Ste 317, Kailua, HI 96734

Open in the dashboard

General payments

$15,994

314 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$18,443 paid to institutions, not to them · program years 2023–2024

Through program year 2025, William Beringer of Kailua, HI is reported in the CMS Open Payments database as having received $15,994 across 314 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $18,443 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 76th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,105 42
2024 General $6,207 46
2023 General $1,230 29
2022 General $1,833 59
2021 General $1,370 36
2020 General $968 26
2019 General $1,283 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Beringer
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to William Beringer were reported at $3,105. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year William Beringer Neurological Surgery median Middle half National median
2019 $1,283 $582 $138–$3,006 $163
2020 $968 $294 $76–$2,174 $114
2021 $1,370 $387 $105–$2,432 $132
2022 $1,833 $542 $139–$2,989 $149
2023 $1,230 $534 $145–$2,697 $160
2024 $6,207 $574 $155–$3,046 $164
2025 $3,105 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $6,310 44 payments
  2. Abbott Laboratories $2,976 56 payments
  3. Boston Scientific Corporation $2,728 117 payments
  4. Nevro Corp. $586 18 payments
  5. Medtronic USA, Inc. $504 25 payments
  6. Orthofix Medical, Inc. $437 5 payments
  7. AbbVie, Inc. $299 8 payments
  8. Zimmer Biomet Holdings, Inc. $298 3 payments
  9. BIOTRONIK NRO, Inc. $275 5 payments
  10. Medacta USA, Inc. $273 3 payments
  11. Other $1,307 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,037 307 payments
  2. Travel and Lodging $4,858 6 payments
  3. Education $99 1 payment
Products named General payments · program years 2019–2025
  1. MAZOR X SYSTEM $4,935 9 payments
  2. PROCLAIM $690 18 payments
  3. General - Pain Management $641 13 payments
  4. INTELLIS Spinal Cord Neurostimulation $620 19 payments
  5. ETERNA Neuromodulation $571 11 payments
  6. ETERNA Structural Heart $462 7 payments
  7. INTELLIS Spinal Cord Neurostimulation $425 23 payments
  8. Proclaim Family of SCS IPGs $421 8 payments
  9. Omnia $408 13 payments
  10. WaveWriter Alpha Prime 16 $404 10 payments
  11. Other $6,177 179 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

22

Median for Neurosurgery: 83

Drug cost

$298

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 22 $298

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$84,529

Medicare's payments for the services billed

Medicare patients

193

Average age 75

Services billed

366

94 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 67%
Ischemic heart disease 32%
Diabetes 30%
Chronic kidney disease 29%
Atrial fibrillation 22%
Osteoporosis 22%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DYSPORT
  • Ipsen Biopharmaceuticals, Inc $55
$55 — —
QULIPTA
  • AbbVie, Inc. $27
$27 — —
Xeomin
  • Merz Pharmaceuticals, LLC $27
$27 — —
UBRELVY
  • AbbVie, Inc. $16
$16 — —
BOTOX
  • AbbVie, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

314 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record